Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)
Fast, easy summary view of NICE guidance on 'lung cancer'
NICE does not recommend erlotinib as maintenance treatment after chemotherapy that contains platinum for people with locally advanced or metastatic non-small-cell lung cancer. Maintenance treatment is sometimes used by people whose cancer did not worsen immediately after having chemotherapy (which is also known as stable disease).
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life if they meet certain criteria. It was not certain whether erlotinib provides enough benefit to patients to justify its high cost and it did not qualify for special consideration, so NICE did not recommend it.
- TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 11 April 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA227 Erlotinib fel triniaeth gynnal ar gyfer canser yr ysgyfaint lle nad yw'r celloedd yn fach: deall canllawiau NICE (fformat MS Word)
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.